DexCom, Inc. (NASDAQ:DXCM – Get Free Report) EVP Jereme Sylvain sold 3,638 shares of DexCom stock in a transaction on Thursday, September 10th. The stock was sold at an average price of $83.27, for a total transaction of $302,936.26. Following the transaction, the executive vice president directly owned 146,828 shares of the company’s stock, valued at $12,226,367.56. The trade was a 2.42% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
DexCom Trading Up 2.0%
DXCM stock traded up $1.65 during mid-day trading on Monday, reaching $84.68. 2,493,694 shares of the stock traded hands, compared to its average volume of 5,119,560. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.43 and a current ratio of 1.73. DexCom, Inc. has a one year low of $54.11 and a one year high of $92.59. The stock has a market capitalization of $31.95 billion, a PE ratio of 33.47, a PEG ratio of 1.39 and a beta of 1.42. The business has a 50-day moving average price of $82.75 and a two-hundred day moving average price of $72.80.
DexCom (NASDAQ:DXCM – Get Free Report) last released its earnings results on Thursday, July 30th. The medical device company reported $0.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.61 by $0.09. DexCom had a net margin of 20.12% and a return on equity of 35.94%. The firm had revenue of $1.31 billion during the quarter, compared to analyst estimates of $1.29 billion. During the same quarter last year, the business earned $0.48 EPS. The business’s revenue was up 13.1% on a year-over-year basis. Equities research analysts expect that DexCom, Inc. will post 2.64 EPS for the current year.
Analysts Set New Price Targets
Check Out Our Latest Stock Report on DXCM
Institutional Trading of DexCom
Several institutional investors and hedge funds have recently modified their holdings of the stock. Reflection Asset Management bought a new position in DexCom in the fourth quarter worth approximately $25,000. Ascentis Independent Advisors purchased a new stake in shares of DexCom in the 1st quarter worth $25,000. MCF Advisors LLC purchased a new stake in shares of DexCom in the 4th quarter worth $32,000. Wellington Grp LLC grew its position in shares of DexCom by 778.7% during the 1st quarter. Wellington Grp LLC now owns 536 shares of the medical device company’s stock worth $34,000 after buying an additional 475 shares in the last quarter. Finally, Cassaday & Co Wealth Management LLC bought a new position in shares of DexCom during the 1st quarter worth $44,000. Institutional investors own 97.75% of the company’s stock.
About DexCom
DexCom, Inc develops and commercializes continuous glucose monitoring (CGM) systems that measure glucose levels in real time. Its technology is designed to help people with diabetes monitor glucose trends and make more informed treatment and lifestyle decisions without relying solely on traditional fingerstick testing.
The company’s products include the Dexcom G7 and Dexcom G6 CGM systems, which use a small wearable sensor, transmitter or integrated sensor, and mobile applications to display glucose data.
Featured Stories
- Five stocks we like better than DexCom
- Analysts Are Punting Their Calls Into the Next Quarter After Adobe’s Mixed Earnings
- Institutional Money Is Pouring Into These 2 Altcoin ETFs
- The End of Big Tech Buybacks? Only One Hyperscaler Is Still Repurchasing Shares
- 3 Dividend Kings to Buy While They’re Still Beaten Down
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.
